Seven Firms Lead on $8.6 Billion Deal for Drugmaker Elan

, The Am Law Daily


Cadwalader, Fried Frank, Gibson Dunn, Morgan Lewis, Sullivan & Cromwell, and leading Irish firms A&L Goodbody and Dillon Eustace are advising on the $6.7 billion cash-and-stock sale of Dublin-based biotechnology company Elan to U.S. generic pharmaceutical firm Perrigo, which will also assume $1.9 billion of the Irish drugmaker's debt. The transaction marks the end of a months-long engagement by corporate and litigation lawyers at Cadwalader on Elan's behalf.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to LexisAdvance®.

Continue to LexisAdvance®

Not a LexisAdvance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via LexisAdvance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202612947666

Thank you!

This article's comments will be reviewed.